Abstract: In certain embodiments, a vial adaptor for removing liquid contents from a vial comprises a housing and a bag. In some embodiments, an initial volume of a regulating fluid can be contained within the bag. In some embodiments, the regulating fluid flows into the vial as liquid is removed from the vial via the adaptor, thereby regulating pressure within the vial. In some embodiments, a vial adaptor is coupled with the vial in order to remove the liquid. In some embodiments, as the liquid is removed from the vial via the adaptor, the bag expands, and in other embodiments, the bag contracts.

Abstract: Methods for making inhalable composite particles comprising a pharmaceutically-active agent, the method comprising: a) providing composite particles comprising a millable grinding matrix and a solid pharmaceutically-active agent, wherein the pharmaceutically-active agent has an median particle size on a volume average basis between 50 nm and 3 ?m; and b) milling the composite particles in a mill without milling bodies for a time period sufficient to produce inhalable composite particles having a mass median aerodynamic diameter between 1 ?m and 20 ?m are described.

Abstract: A medication dispenser having a housing adapted to securely retain patient medication until such a time as a controller enables a patient interface to permit a patient to access medication stored and distributed by the dispensing assembly.

Abstract: Methods and systems are described for monitoring medication use with a home automation system. An example medication monitoring system includes a medication storage device, a proximity device, and a dispenser module. The medication storage device is configured to hold a plurality of medications. The proximity device is configured to detect an activity of a user relative to the medication storage device. The dispense module is configured to detect a pattern of the activity based on data received from the proximity device, and generate a notice. The notice may be generated if the pattern is broken. The notice may include a summary report on usage of the medication storage device. The notice may include an alarm if the medication storage device is, for example, tampered with or moved.

Abstract: Presently described are dental compositions comprising one or more fatty mono(meth)acrylates, methods of use, dental articles, and methods of making dental compositions. It has been found that a relatively low concentration of a fatty mono(meth)acrylate can improve the handling characteristics of a dental composition by reducing the tendency of the composition to stick to a dental instrument and/or by reducing the tendency of a dental composition to string when being manipulated by a dental instrument. In one embodiment, a hardenable dental composition is described comprising a polymerizable resin composition comprising at least one multifunctional ethylenically unsaturated monomer; 0.2 to 10 wt-% of one or more fatty mono(meth)acrylate monomers; and at least 50 wt-% of inorganic oxide filler.

Abstract: A hardenable two part acrylic composition is described for the treatment of human or animal bone is described. The composition comprises a storage stable liquid first part and a storage stable liquid second part which react with each other upon mixing to form a cement which hardens. The composition further comprises an acrylic monomer component and an initiator component in an amount effective to polymerize the monomer component. The monomer component and the initiator component are generally located in separate parts of the two part composition so that the monomer component is storage stable. The liquid first part comprises emulsion polymerized acrylic polymer particles in a liquid carrier. A method of producing a hardenable two part acrylic composition is also described. The composition is particularly useful in a syringe or caulking gun having at least two barrels.

Abstract: The present invention relates to methods and products, such as wet wipes and absorbent articles, that are capable of imparting a health benefit when used in the intended fashion. More specifically, the products described herein comprise one or more botanical compounds, which are capable of selectively controlling the balance of flora on the skin. The compounds may enhance the adherence of healthy flora to the surface of skin or mucosa, inhibit the growth of problem flora on or around the skin surface, or inhibit the adherence of problem flora to the surface of skin or mucosa, or any combination thereof.

Abstract: The present invention relates to a composition, for inhibiting dental erosion, and the use thereof. The composition comprises an aqueous solution of hydrofluoric acid, in which the concentration of hydrofluoric acid is 0.05%-2.00% and the pH is between 2.5 and 4.5.

Abstract: An antimicrobial mixture comprising or consisting of: one or more compounds of the formula (I) their salts or solvates, wherein R1 and R2 in each case independently of one another are chosen from the group consisting of: H, OH, F, Cl, Br and I, and wherein X in each case denotes: (CH2)m where m=1, 2 or 3 or OCH2n where n=1, 2 or 3 or O—CH2—CH(R3) where R3=CH3 or CH2OH or (CH2—OpCH2 where p=1 or 2, wherein in the compound(s) of the formula I a primary alcohol function CH2OH is optionally replaced by a radical which is chosen from the group consisting of CH2OR4, COOH and COOR4 and/or a secondary alcohol function CHOH is optionally replaced by the radical CHOR4, wherein each R4 denotes an aliphatic or aromatic radical, independently of the meaning of further radicals, and one, two or more compounds chosen from the group consisting of the tropolones of the formula (II) wherein the substituents R5, R6, R7, R8, R9 independently of one another have the following meaning: H; linear or branched

Abstract: The disclosure comprises a process that pertains to the chemical reaction of hair when exposed to a series of chemical compositions. Utilization of named ingredients in specified order manipulates the pH value and driving agents; the nature of the process is an improvement of delivery methods for hair strengthening and smoothing treatments.

Abstract: The disclosure relates to a method for gradually coloring hair comprising the steps of: a) applying an air oxidation haircolor composition to hair; b) removing the air oxidation haircolor composition from the hair directly after application; and c) repeating a set comprising the steps a) and b) in multiple spaced intervals. The air oxidation haircolor composition can include: 1) at least one primary oxidation dye intermediate; 2) at least one aromatic triol; and 3) water.

Abstract: A mesenchymal stem cell extract and its use are provided, wherein the mesenchymal stem cell extract comprises a trophic factor(s), such as bone morphogenetic protein-7 (BMP-7), stromal cell-derived factor-1 (SDF-1), vascular endothelial growth factor (VEGF), C-X-C chemokine receptor type-4 (CXCR4), brain-derived neurotrophic factor (BDNF), and/or interleukin-17 (IL-17), and wherein the extract is especially suitable for repairing skin aging.

Abstract: Compositions of the invention comprise 8-oxoguanine glycosylase (OGG1) and SIRT6 activating peptide G-A-G-V-S-A-E-NH2. Compositions of the invention exhibit anti-aging effects by promoting the repair of skin cell DNA and/or by protecting skin cell DNA from UV damage.

Abstract: The cosmetic or non-therapeutic use of an oral composition for reinforcing an individual's skin tolerance to topical administration of a retinoid compound, the oral composition having at least one carotenoid, at least one phytoestrogen and vitamin C. A cosmetic or non-therapeutic process for increasing an individual's skin tolerance to topical administration of a retinoid compound, having at least one step of oral administration to the individual of an oral composition having at least one carotenoid, at least one phytoestrogen and vitamin C. A set for simultaneous, separate or sequential administration, the set having a first cosmetic composition for topical application having, in a physiologically acceptable medium, at least one effective amount of a retinoid compound, and a second composition for oral administration, for reinforcing the skin tolerance of the individual treated with the first composition, the second composition having at least one carotenoid, at least one phytoestrogen and vitamin C.

Abstract: A solid cosmetic composition includes (i) corn starch in an amount of from about 20% to about 40%; (ii) bulking agent in an amount of from about 20% to about 50%; (iii) surfactant in an amount of from about 5% to about 30%; and (iv) glycerine in an amount of from about 15% to about 30%, present in an amount by weight of the total composition.

Abstract: The present specification relates to a composition comprising processed ginseng extract and processed green tea extract. Such a composition results in having a synergistic effect due to mixing of each processed extract, and is thus capable of promoting the production of procollagen and inhibiting the expression of collagenase. In addition, the composition of the present specification promotes the expression of filaggrin and is thus capable of strengthening a skin barrier function and inducing the differentiation of skin keratinocytes. Therefore, the composition of the present specification is capable of improving the general condition of skin, and can be effectively used as an external preparation for skin for preventing or improving xeroderma, atopic dermatitis, contact dermatitis, psoriasis, or the like that is caused by the imperfection of epidermal differentiation.

Abstract: This invention provides an effervescent solid form that dissolves in cold water quickly enough to not disappoint consumers yet not so quickly that the visual interest generated during the effervescent reaction is lost. This performance is achieved by forming effervescent particles that are dense enough to retard dissolution and small enough to not take too long to dissolve. The aim of this invention is to provide a beverage in solid effervescent form that takes between about 30 and about 120 seconds to dissolve in warm water. The granules may carry functional additives such as flavors, vitamins, minerals, sweeteners, colors and drugs. The granules may also be compounded of materials intended to provide relief from skin or topical discomfort, as in the form of a wash or bath additive. The granules may also be formulated to provide cleaning agents, such as ceramic cleaners and denture cleaners.

Abstract: An objective of the present invention is to provide stable antibody-containing formulations which are suitable for subcutaneous administration and in which aggregation formation is suppressed during long-term storage. The present inventors discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid as a counter ion species in histidine buffer or tris(hydroxymethyl)aminomethane, specifically by using histidine-aspartate buffer or histidine-glutamate buffer, or tris(hydroxymethyl)aminomethane-aspartate or tris(hydroxymethyl)aminomethane-glutamate as a buffer. The present inventors also discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid, as a counter ion species to a basic amino acid such as arginine, specifically by using arginine-aspartate or arginine-glutamate.

Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.

Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In certain embodiments, the dose of tramadol about 25 mg and the second (and optionally) third doses are intravenously administered at intervals of about 2 hours, and thereafter the tramadol is intravenously administered at a dosing interval of about 4 hours, until the patient no longer requires treatment with tramadol.

Abstract: A method of coating a material onto projections provided on a patch. The method includes applying a coating solution containing the material to at least the projections and drying the coating solution to at least the projections using a gas flow.

Abstract: The present invention concerns a method for making an inhaled pharmaceutical composition with improved powder handling properties comprising a stearate, a method of preparing such a composition, and the use of such a stearate in a composition when dispensed into a receptacle for use in a dry powder inhaler receptacle.

Abstract: PSA-PCL micelles were developed as carrier systems for pharmaceutical drugs. As an example, cyclosporine A (CyA) was encapsulated in the micelles and physical characterization, including size and zeta potential, demonstrated that the micelles possess favorable properties for drug delivery. In vitro studies verified that rheumatoid arthritis synovial fibroblasts are able to internalize the CyA-loaded micelles. CyA was released from the PSA-PCL micelle upon uptake and subsequently, partitioned into the phospholipid membrane. The PSA-PCL micelles also demonstrated improved therapeutic efficacy in drug delivery when used to deliver statins and disease modifying anti-rheumatic drugs (DMARDs).

Abstract: The present invention provides compositions and methods for the treatment of cancer are provided.

Abstract: Liposomal compositions comprising peptide epoxyketone compounds are described, as well as methods of making and using such liposomal compositions. These liposomal compositions enhance the therapeutic window of peptide epoxyketone compounds by improving in vivo half-life relative to non-liposomal compositions comprising peptide epoxyketone compounds, providing desirable pharmacodynamic profiles, and providing anti-tumor activity in a human tumor xenograft model, greater than or equal to non-liposomal compositions comprising peptide epoxyketone compounds. Further, experiments performed in support of the present invention demonstrated improved tolerability of liposomal compositions comprising peptide epoxyketone compounds.

Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g.

Abstract: A particulate solid composition comprises a blend of dialkyl sulfosuccinate and a water-soluble polymer. The water-soluble polymer can be a cellulose ether, a polysaccharide, a polyvinyl alcohol homopolymer or copolymer, a polyvinyl pyrrolidone homopolymer or copolymer, a polyvinyl caprolactam polymer or copolymer, a poly(meth)acrylate, a poly(alkylene oxide) graft copolymer, or a combination thereof. The particulate solid composition is free flowing, water-soluble, and dissolves rapidly in water. It can be made by drying a solution of dialkyl sulfosuccinate and a water-soluble polymer. The particulate solid composition can be mixed with organic substances having low water solubility, for example a generic, a biologic, a biosimilar, an excipient, a nutraceutical, a medical diagnostic agent, an agricultural chemical, or a combination thereof, to form water-soluble compositions.

Abstract: An edible energy tablet containing at least 80 weight % carbohydrates for consumption during exercise, is fabricated by a process including providing tablet material free of hydrophobic and/or PEG lubricants and free of CO2 sources. The tablet material includes a sucrose and dextrose mixture of 77-95 wt. %, maltodextrin of 2-13 wt. %, an edible soluble oil of 0.2-2.0 wt. %, and an edible acid of 1-4 wt. %. The tablet material is introduced to a tablet press that alternately moves first and second punches towards and away from one another to compress the tablet material to form and release a tablet. A punch cleaner engaged with the first and second punches removes tablet material from the punches after tablet release. The tablet has a diameter of 1.2 to 3.8 cm, a thickness of 0.6 cm to 2.3 cm, and a resistance to breakage forces of 8.5 to 30 kilopounds.

Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.

Abstract: A coating agent imparts gas barrier properties to a solid preparation while keeping rapid disintegration properties of the solid preparation, and a coating formed therewith, and provides a coated solid preparation that maintains its rapid disintegration properties and gas barrier properties, and does not generate cracks in the coating under humidified conditions. The coating agent for a solid preparation contains lactose and a swelling clay, but does not contain a water-soluble polymer, wherein the weight of the swelling clay is 20 to 50% with respect to the weight of the solid content.

Abstract: A porous hollow silica particle with an interpolymer complex immobilized thereon is provided. The interpolymer complex comprises a first polymer immobilized to a surface of the silica particle, and a second polymer complexed with the first polymer. Pharmaceutical compositions comprising the silica particle, and methods of forming the silica particle are also provided.

Abstract: A computer-implemented method for image-guided delivery of a nanoparticle mixture to a target tumor located in a region of interest includes selecting a non-hypoxic delivery location within the region of interest for delivery of a non-bacteria-associated nanoparticle component included in the nanoparticle mixture and selecting a hypoxic delivery location within the region of interest for delivery of a bacteria-associated nanoparticle component included in the nanoparticle mixture. An image-guided delivery and monitoring process may then be performed.

Abstract: Cationic polymers are provided for delivering anionic active agents, preferably in the form or nanoparticles and other nanostructures. The polymer can be a polycation homopolymer or a copolymer containing a polycation block. The polycations and polycation containing polymers can contain dicarboxylic acid ester units and units of (a-amino acid)-?, ?-alkylene diester units. The nanoparticles can contain high loadings of anionic active agents, with sustained release of the active agents. Methods of making the polycations and polycation containing polymers are provided. Methods of making the nanoparticles and formulating them for administration to an individual in need thereof are also provided.

Abstract: Methods of producing a Hydrophilic Homeopathic Aqueous Substance Active (HASA)-gel matrix, include the steps of: (a) combining a homeopathic compound and an uninhibited aqueous composition to produce a HASA; (b) combining the HASA with at least one hydrophilic gelling agent; and (c) thereafter, forming the hydrophilic HASA-gel matrix by use of at least one of a thickening agent, a crosslinking agent, or a polymerization agent.

Abstract: A patch containing free ropinirole (ropinirole in free form) in an adhesive base is provided, in which the patch exhibits favorable and continuous transdermal absorbability, high drug stability, and excellent adhesiveness. A transdermal absorption patch includes free ropinirole added to an adhesive base that contains a styrene-isoprene-styrene block copolymer (SIS), one or two or more tackifier resins containing a rosin-based resin, and a softener. The transdermal absorption patch is characterized in that the compounding ratio of the rosin-based resin to the free ropinirole represented as the ratio of the weight of the combined rosin-based resin to the free ropinirole is 3.5 to 8.0. In particular, a ropinirole-containing patch wherein the rosin-based resin is a hydrogenated rosin glycerol ester and the softener is liquid paraffin is provided.

Abstract: The present invention relates to formulation of sparingly-(water)-soluble compounds and its use as (or in a) food or feed product or dietary supplement.

Abstract: This disclosure describes compounds that affect the olfactory responses of the honey bee mite (Varroa destructor) and methods of use thereof. The compounds do not kill Varroa destructor, and are therefore unlikely to generate Varroa destructor resistance, compared to an acaricide. The compounds can work in conjunction with other mite control approaches, such as a bottom board excluder and sticky board control devices, and can enhance the performance of other forms of mite control while decreasing disadvantages associated therewith.

Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes. Also disclosed are methods of treating respiratory illness through administration of a composition comprising phenylephrine, its free and addition salt forms, and mixtures thereof alone, or in combination with other pharmaceutical actives, wherein the composition has a pH of from about 2 to about 5 and is substantially free of aldehydes.

Abstract: Topical sphingosine-1-phosphate receptor agonist active agent formulations are provided. Aspects of the transdermal formulations include an amount of a sphingosine-1-phosphate receptor agonist active agent in combination with a topical delivery vehicle, e.g., a topical patch that includes an adhesive layer and a backing layer. Also provided are methods of topically delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat a subject for a disease condition, such as an immune system disorder like multiple sclerosis, a hyperproliferative dermatological disorder, e.g., psoriasis, acne, etc. Packaged topical formulations, kits including such formulations, and methods of making such formulations are also provided.

Abstract: The present invention provides methods of preventing and/or reducing risk of neurodegeneration of association cortex, and/or inhibiting or reversing formation of phosphorylated tau or COXIV in the prefrontal cortex of a mammal in need thereof. In certain embodiments, the method comprises administering to the mammal a therapeutically effective amount of an ?2A-adrenergic receptor agonist.

Abstract: Methods and compositions for sensitizing multiple myeloma cells to treatment with IMiDs are provided. Aspects include methods of administering AR-42 and an IMiD (e.g., lenalidomide, pomalidomide) to multiple myeloma patients.

Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.

Abstract: Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.

Abstract: The object of the present invention is to provide a hangover prophylactic and/or therapeutic agent. The present invention provides a hangover prophylactic and/or therapeutic agent comprising ALAs.

Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).

Abstract: Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided.

Abstract: The present invention relates to a topical solution comprising a retinoid or its pharmaceutically acceptable salts thereof and process of preparing it.

Abstract: Cadotril particles suitable for solid or liquid dosage forms are the subject of this application.

Abstract: The present invention relates to a microelement organic O-chelate or N-chelate complex compound, for the inhibition of facultative pathogenic bacteria. The present invention further relates to a composition, feed additive or feed comprising the compounds, as well as methods for the preparation thereof, and for the use thereof in animal stock farming.

Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.